Investigational Drug Information for PF-06882961
✉ Email this page to a colleague
What is the development status for investigational drug PF-06882961?
PF-06882961 is an investigational drug.
There have been 15 clinical trials for PF-06882961.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 15th 2019.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Obesity. The leading clinical trial sponsors are Pfizer and [disabled in preview].
There are four US patents protecting this investigational drug and sixty-two international patents.
Summary for PF-06882961
| US Patents | 4 |
| International Patents | 62 |
| US Patent Applications | 21 |
| WIPO Patent Applications | 11 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 2 (2019-10-15) |
| Vendors | 19 |
Recent Clinical Trials for PF-06882961
| Title | Sponsor | Phase |
|---|---|---|
| STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS | Pfizer | Phase 1 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus | Pfizer | Phase 1 |
| A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy | Pfizer | Phase 1 |
Clinical Trial Summary for PF-06882961
Top disease conditions for PF-06882961
Top clinical trial sponsors for PF-06882961
US Patents for PF-06882961
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-06882961 | ⤷ Try a Trial | GLP-1 receptor agonists and uses thereof | Pfizer Inc. (New York, NY) | ⤷ Try a Trial |
| PF-06882961 | ⤷ Try a Trial | GLP-1 receptor agonists and uses thereof | Pfizer Inc. (New York, NY) | ⤷ Try a Trial |
| PF-06882961 | ⤷ Try a Trial | GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (Shanghai, CN) | ⤷ Try a Trial |
| PF-06882961 | ⤷ Try a Trial | GLP-1 receptor agonists and uses thereof | Pfizer Inc. (New York, NY) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-06882961
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-06882961 | Argentina | AR110387 | 2036-12-16 | ⤷ Try a Trial |
| PF-06882961 | Australia | AU2017374860 | 2036-12-16 | ⤷ Try a Trial |
| PF-06882961 | Brazil | BR112019012211 | 2036-12-16 | ⤷ Try a Trial |
| PF-06882961 | Canada | CA2988721 | 2036-12-16 | ⤷ Try a Trial |
| PF-06882961 | Chile | CL2019001651 | 2036-12-16 | ⤷ Try a Trial |
| PF-06882961 | China | CN110325530 | 2036-12-16 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
